polyethyleneglycol3350
ApprovedSmall molecule
polyethyleneglycol3350 is one of 23 small molecule programs targeting Constipation. It is currently in Approved.
2
Indications
5
Total Trials
0
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
40 competitors in Chronic Constipation
#DrugCompanyPhaseTrials
1Resotran
TakedaApproved
Golytely
BayerApproved
Linzess
AbbViePhase 3
Zelnorm
AAlfasigma S.p.A.
Phase 3
Chronulac
SSolvay Pharmaceuticals
Phase 3
Lactobacillus Reuteri
TTulane University School of Medicine
Phase 3
Amitiza
SSucampo Pharma Americas, LLC
Phase 2
Elobixibat
FerringApproved
polyethyleneglycol3350
BBraintree Laboratories
Approved
E. Coli Nissle 1917
KKangbuk Samsung Hospital
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Constipation1 trial
Chronic constipation1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for polyethyleneglycol3350. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- BBraintree Laboratories